OmniAb Inc. (OABI)
OABI trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1846253/000184625326000009/0001846253-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OABI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001846253 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $18.7M |
| Net income | -$64.8M |
| Operating income | -$69.0M |
| Net margin | -347.0% |
| Operating margin | -369.5% |
| Revenue growth | -29.3% |
| Cash | $25.5M |
| Total assets | $300.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 38.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $22.9M cash; operating cash flow $667K a quarter. | Report 2026-09-30 |
| Shares outstanding | 145,860,318 (2026-10-23); 143,955,400 a year earlier; 116,238,186 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $108K, sold $283K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.0M | -$15.7M | $10.6M | $22.9M | No debt tags | $40.2M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $13.4M | -$5.9M | $2.7M | $24.3M | No debt tags | $38.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $14.4M | -$7.7M | -$4.9M | $29.0M | No debt tags | $28.9M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $8.4M | -$14.2M | -$5.7M | $25.5M | No debt tags | $18.7M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $2.2M | -$16.5M | -$9.8M | $28.5M | No debt tags | $21.1M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $3.9M | -$15.9M | -$5.1M | $18.3M | No debt tags | $23.0M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $4.2M | -$18.2M | -$15.9M | $10.9M | No debt tags | $26.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $10.8M | -$13.1M | -$3.9M | $27.6M | No debt tags | $26.4M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-09-12 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 387 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.4% |
| 1 month | +4.5% |
| 3 months | +43.1% |
| Year to date | +165.4% |
| 1 year | +223.0% |
| From 52-week high | -7.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| OABIW | OmniAb Inc. Warrant | $0.4100 |
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| ONMD | OneMedNet Corp | $4.86 | -8.99% | $29.2M |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier